Metoprolol vs ace inhibitors
Pro Research Analysisby 
Searched over 200M research papers
Metoprolol vs ACE Inhibitors: Efficacy in Cardiac and Renal Outcomes
Blood Pressure and Cardiac Function in Hypertension and Heart Disease
Both metoprolol (a beta-blocker) and ACE inhibitors like enalapril and ramipril are effective in lowering blood pressure and are commonly used in patients with hypertension and cardiac conditions. Studies comparing these drugs in patients with hypertension complicated by coronary heart disease found that combining enalapril with metoprolol led to greater reductions in blood pressure and improved cardiac function compared to enalapril alone. The combination also reduced inflammatory markers more effectively, with no significant increase in adverse reactions, suggesting a potential benefit of using both drugs together in these patients .
Heart Failure and Myocardial Infarction: Comparative Effects
In patients with heart failure or after myocardial infarction, both ACE inhibitors and beta-blockers are standard therapies. Research in animal models of myocardial infarction showed that both metoprolol and ACE inhibitors improved heart healing, but ACE inhibitors and certain beta-blockers like carvedilol were more effective than metoprolol in reducing harmful collagen buildup in the heart. This suggests that while metoprolol is beneficial, ACE inhibitors and some other beta-blockers may offer additional protection against heart remodeling after injury .
Renal and Cardiac Effects in Chronic Kidney Disease
In patients with autosomal dominant polycystic kidney disease (ADPKD) and hypertension, studies found no significant differences between ramipril (an ACE inhibitor) and metoprolol in terms of preserving kidney function, reducing urinary albumin excretion, or preventing heart muscle thickening over three years. The key factor in slowing disease progression was rigorous blood pressure control, regardless of which drug was used 46.
Cerebral Blood Flow and Anesthesia Considerations
When considering the effects on cerebral blood flow during anesthesia, metoprolol did not significantly alter cerebral blood flow compared to controls. However, pretreatment with the ACE inhibitor captopril led to lower cerebral blood flow and mean arterial pressure, suggesting that ACE inhibitors may need to be discontinued before anesthesia to avoid low blood pressure and reduced brain perfusion .
Mechanisms of Action and Biomarker Effects
ACE inhibitors and metoprolol have different effects on certain biomarkers. For example, ACE inhibitors reduce plasma neuropeptide Y (NPY) concentrations, while metoprolol does not. This difference may contribute to their distinct mechanisms in lowering blood pressure and protecting the heart and blood vessels .
Use in Combination Therapy
Combination therapy with ACE inhibitors and beta-blockers is common, especially in patients with high cardiovascular risk, such as those with diabetes or after myocardial infarction. Clinical practice data show that a significant proportion of patients receive both drug types, with metoprolol being a frequently prescribed beta-blocker alongside ACE inhibitors 79. Some evidence suggests that carvedilol may be superior to metoprolol in certain metabolic outcomes, but direct comparisons are limited .
Cancer Recurrence Risk
In a large cohort of breast cancer patients, neither beta-blockers (including metoprolol) nor ACE inhibitors were associated with a reduced risk of cancer recurrence. In fact, metoprolol was linked to a slightly increased risk of recurrence, though the clinical significance of this finding is uncertain .
Conclusion
Metoprolol and ACE inhibitors are both effective for managing hypertension and protecting heart and kidney function. Their benefits are often similar, especially when blood pressure is well controlled. Combination therapy may offer additional advantages in certain patients, particularly those with coronary heart disease. The choice between these drugs should be individualized based on patient characteristics, comorbidities, and treatment goals.
Sources and full results
Most relevant research papers on this topic
Renal and cardiac effects of antihypertensive treatment with ramipril vs metoprolol in autosomal dominant polycystic kidney disease.
Ramipril and metoprolol both effectively lower blood pressure in hypertensive ADPKD patients, with no significant differences in renal function, urinary albumin excretion, or left ventricular mass index.
DOI
Renal and cardiac effects of antihypertensive treatment with ramipril versus metoprolol in autosomal dominant polycystic kidney disease.
Both ramipril and metoprolol effectively lower blood pressure in hypertensive ADPKD patients, with no significant differences in renal function, urinary albumin excretion, or LVMI.
DOI